RICHMOND, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic
exoskeleton company, today announced the appointment of Matthias Stief as Managing Director of Ekso Bionics Europe GmbH effective
immediately. In this position, Matthias will lead and manage all sales and marketing activities in the Europe, Middle East
and Africa (EMEA) region.
"It is a privilege to welcome Matthias to build our European business at this very exciting juncture for Ekso
Bionics," said Tom Looby, Chief Executive Officer of Ekso Bionics. "He is a highly accomplished executive with a strong
background leading international organizations within the medical device industry, whom I have had the privilege of working closely
with in the past. His experience will be invaluable as we continue to build the Ekso Bionics business outside the U.S.”
Mr. Stief brings to Ekso Bionics over 20 years of international sales, marketing and operational experience in a
variety of medical device companies, most recently having served as Managing Director EMEA for EndoChoice, a developer of
innovative endoscopy systems and single-use products. Prior to EndoChoice, from 2004-2013, Mr. Stief served in many
positions at Given Imaging, a developer of video capsule endoscopy products, where he developed a sales and marketing team and
distributor market in EMEA, ultimately as Vice President of Marketing and Sales EMEA. Mr. Stief previously served in various
sales and marketing positions for Pentax Europe, Siemssen & Co and Hoyer Medizintechnik.
"The Ekso GT has consistently set itself apart as a safe and effective rehabilitation tool for patients recovering from stroke
and spinal cord injury, with the real potential to become standard of care for the rehabilitation paradigm," said Mr. Stief.
"I look forward to joining Ekso Bionics at such an important time and to helping the company realize its full potential and
achieve the goal of maximizing shareholder value."
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength,
endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon
its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso
Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended
to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under
the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord
injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only
exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s
body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability
to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped
patients take more than 55 million steps in over 120 rehabilitation institutions around the world.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons,
(ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items,
(iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in
points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many
of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or
desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's
operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the
development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the
failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical
studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology,
failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification,
existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and
other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics
please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking
statements.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 cyamond@lazarpartners.com Investor Contact: Debbie Kaster 415-937-5403 investors@eksobionics.com
